Carlson Capital’s AstraZeneca AZN Stock Holding History

Carlson Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-37,000	Closed	-$2.99M	–	254
2019 Q1	$2.99M	Buy	+37,000	New	+$2.92M	0.05%	215
2016 Q2	–	Sell	-219,150	Closed	-$12.3M	–	286
2016 Q1	$12.3M	Buy	219,150 +45,550	+26%	+$2.74M	0.15%	177
2015 Q4	$11.8M	Buy	+173,600	New	+$11.4M	0.13%	190
2015 Q1	–	Sell	-48,000	Closed	-$3.38M	–	317
2014 Q4	$3.38M	Sell	48,000 -39,000	-45%	-$2.79M	0.03%	280
2014 Q3	$6.21M	Sell	87,000 -25,100	-22%	-$1.84M	0.07%	267
2014 Q2	$8.33M	Buy	+112,100	New	+$8.1M	0.09%	259

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Carlson Capital's AZN Position: Q2 2019 in Review

Carlson Capital sold out of AstraZeneca (AZN) in Q2 2019, closing a stake of 37,000 shares — an estimated $2.99M sold.

Carlson Capital first reported a position in AZN in Q2 2014 and held it in 6 quarters. The position peaked at $12.3M in Q1 2016. 546 funds tracked by Wall St. Rank hold AZN as of Q2 2019.

Carlson Capital reported no remaining AstraZeneca position as of Q2 2019 after selling out during the quarter.
Carlson Capital sold 37,000 AstraZeneca shares in Q2 2019, an estimated $2.99M.
Carlson Capital first reported a position in AstraZeneca in Q2 2014 and held it in 6 quarters.
Carlson Capital's AstraZeneca position peaked at $12.3M in Q1 2016.
546 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2019.

Based on Carlson Capital's 13F filing for Q2 2019, filed 12 Aug 2019.